Look there
13 October 2020

The $390 bln firm paused its Covid-19 vaccine trial – and raised estimates amid rising demand for everything from Tylenol to oncology drugs. The shares fell. Whether the halt means anything is unclear. It’s also of little importance relative to J&J’s core business.